As drug­mak­ers pre­pare for the loom­ing bio­phar­ma patent cliff, 2026 has so far been a year for deal­mak­ing. Now, con­tract man­u­fac­tur­ers need to broad­en...

Te­va is bet­ting it has enough room to ad­e­quate­ly pre­pare for steep tar­iffs the Trump ad­min­is­tra­tion plans to slap on gener­ic drugs made out­side the...

Just a lit­tle over six months in­to his tenure as CEO at GSK, Luke Miels is mak­ing his mark.

The drug­mak­er on Tues­day out­lined plans...

The FDA said it will end a pi­lot that was in­tend­ed to help drug­mak­ers proac­tive­ly ad­dress pro­duc­tion is­sues. Few com­pa­nies took ad­van­tage of the pro­gram...

Plus, news about Te­va.

💶 Ger­resheimer sells two sub­sidiaries to pri­vate eq­ui­ty: Ger­resheimer is di­vest­ingits Cen­tor and Pri­ma­ry Pack­ag­ing Plas­tics (PPP) busi­ness­es to pri­vate...

Leqem­bi, the an­ti-amy­loid Alzheimer’s drug from Ei­sai and Bio­gen, record­ed $184 mil­lion in glob­al sales in the sec­ond quar­ter, Bio­gen said Wednes­day morn­ing.

It's the...

Af­ter two days of meet­ings, an FDA ad­vi­so­ry com­mit­tee last week vot­ed to lift re­stric­tions on six pop­u­lar health and well­ness pep­tides, set­ting aside FDA...